Shares in Bristol-Myers Squibb were given a nudge after US regulators accepted an application to expand the use of its immunotherapy Opdivo in lung cancer. The firm has filed a supplemental Biologics ...

US regulators have accepted Bristol-Myers Squibb’s application to market its immunotherapy Opdivo plus Yervoy for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in certain ...

Specifically, the partners are seeking approval of Erbitux (cetuximab) in combination with irinotecan for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing ...

Bristol-Myers Squibb (BMS) has filed for approval of a fixed-dose combination of its HIV drug Reyataz with Gilead Sciences’ cobicistat in the US. The product combines BMS’ successful HIV protease ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...

Two months after BMS fended off a lawsuit which accused it of using anticompetitive tactics, it is back in court, facing a similar lawsuit from Cigna.